| Factor Information | |
|---|---|
| Data ID | 4171 |
| Factor | Relative mortality risk after pulmonary valve replacement(age brackets of 35–40) |
| Description | The age brackets of 35–40, 40–45 and >50 were associated with increased mortality risk compared to the baseline bracket of 15–20, with P-values <0.1. |
| Biomarker | NA |
| Classification | A3 (clinical factor - disease & symptom) |
| Association | |
|---|---|
| Application | risk assessment |
| Objective | To evaluate the impact of age at PVR(pulmonary valve replacement) on outcomes |
| p Value | 0.07 |
| HR | 4.8 |
| Conclusion | The age brackets of 35–40, 40–45 and >50 were associated with increased mortality risk compared to the baseline bracket of 15–20, with P-values <0.1. |
| Risk Factor | unrelated |
| CHD Type | |
|---|---|
| ID | 53 |
| CHD Type | isolated CHD |
| CHD Subtype | TOF |
| Reference | |
|---|---|
| PMID | 32187367 |
| Year | 2020 |
| Title | Age over 35 years is associated with increased mortality after pulmonary valve replacement in repaired tetralogy of Fallot: results from the UK National Congenital Heart Disease Audit database |
| Sample | ||
|---|---|---|
| Population | adolecents, adults | |
| Source | patients | |
| Region | London, UK | |
| Method | retrospective study | |
| Race | European | |
| Disease History | with 5.1% genetic conditions | |
| Treatment History | pulmonary valve replacement | |
| Group | age of 35–40(Treatment) | age of 15–20(Control) |
| Number | 71 | 163 |
| Age | 35–40 years | 15–20 years |
| Gender (Male: Female) | 385:321 | 385:321 |
| Marker Level | hazard ratio:4.8 | hazard ratio:baseline |
